Please select the option that best describes you:
How do you approach the diagnostic evaluation of osteoporosis in CKD when renal dysfunction limits use of certain tests or biomarkers?
This question is part of our collaboration with ACR Convergence 2025 to Continue the Conversation from the meeting. This question was inspired by the session "Updates in Osteoporosis: Where They 'Fall Short" by Dr. @Sharon Moe and Dr. @Elaine W. Yu. If you did not attend the meeting, information about Convergence On Demand can be found here.
Answer from: at Academic Institution
DEXA is still appropriate, and if anything, would underestimate the actual bone loss. For serum biomarkers, only TRAP5B, bone-specific Alkaline phosphatase (BSAP), and PINP are not altered with renal impairment (i.e., not partially cleared by the kidneys, leading to circulating fragments that render...
Sign In or Register to read more